VRG Therapeutics is developing a miniprotein-based drug candidate that targets the Kv1.3 ion channel, a membrane pore implicated in certain autoimmune and chronic inflammatory disorders. Indications mentioned by the company include inflammatory bowel disease, atopic dermatitis, rheumatoid arthritis and multiple sclerosis.
According to VRG, miniproteins occupy a middle ground between antibodies and small-molecule drugs: they are large enough to bind substantial surface area on a target yet smaller and more designable than antibodies. This makes them suitable for addressing targets that are difficult to modulate with conventional small molecules, such as ion channels.
Role of artificial intelligence and accelerated timelines
VRG’s development process begins with computer-aided design in an in silico stage: models and AI tools generate initial candidate molecules, which are then tested experimentally. In the company's roughly 600-square-metre laboratory, researchers evaluate how AI-designed molecules behave with proteins and cells, followed by efficacy and safety testing in animal models.
The company says AI’s main current benefit is providing better starting points: fewer but higher-quality candidates progress to costly experimental testing. Whereas it previously took roughly 2.5–3 years to move from concept to animal testing, VRG reports that this can now be shortened to under one year in ideal cases, and in extreme cases to around six months.
VRG stresses that laboratory validation remains indispensable: computers do not produce finished drugs by themselves, but they substantially speed up and improve candidate selection. Experimental data generated in-house are fed back into the design cycle to refine future candidates.
International partnership with AOP Health
A notable milestone for the Kv1.3 program is the involvement of Austrian partner AOP Health. VRG says a pharmaceutical partner’s participation represents not only financial support but also scientific validation — a signal that a larger industry player sees commercial potential in the project. The partnership increases visibility and credibility with investors and can reduce perceived technological risk.
The program is currently at the end of the preclinical stage before human testing. To proceed, VRG needs to complete two main areas: establish manufacturing and quality control processes to produce the molecule reproducibly at clinical-grade quality, and complete toxicology studies to demonstrate sufficient safety for first-in-human trials. Once these data are compiled, they can be submitted to regulators for approval to start clinical trials.
From first-in-human trials to patients
If regulators approve the submission, the program would begin with small Phase 1 trials in healthy volunteers to assess safety. If safety is confirmed, subsequent trials would evaluate efficacy in patients and ultimately require larger studies to demonstrate that the drug works and is safe — a process that takes several years even in optimal scenarios. VRG emphasizes that progress depends on each successive experiment, and unexpected issues can arise later despite promising preclinical data.
Other programs spun out as separate companies
Two other development directions originating at VRG have been advanced in separate companies: CREATe Therapeutics and Novamigra.
-
CREATe Therapeutics is working on a gene therapy concept in which a drug-like molecule would act as a switch to turn the therapeutic gene on or off. This would enable spatially and temporally controlled interventions, for example in a specific brain region, and could be relevant to disorders such as drug-resistant focal epilepsy.
-
Novamigra is developing a migraine-prevention drug combination in which two known types of active compounds, which individually showed limited effects, may potentiate each other when combined. The Novamigra VRG-145 program is already in preparation for initial human studies.
VRG says these activities are separated into distinct companies because they involve different technologies and investor logic; what appeals to an investor in miniproteins may not match the profile for gene therapy or migraine prevention.
Hungarian innovation ecosystem: strengths and bottlenecks
VRG’s origins date to the mid-2010s, when two Hungarian physicians set out to create a drug development group. The company notes that Hungary benefits from a pharmaceutical heritage and large domestic companies such as Richter and Egis, but faces shortages in experienced drug-development managers. It can be personally risky for professionals to leave secure corporate positions for a small biotech startup.
Another major challenge is capital: drug development is capital-intensive and risky. While successful drugs can generate substantial returns, early-stage investors in Hungary are often less willing to accept the high risk profile required for lengthy pharmaceutical development.
Summary
VRG Therapeutics’ miniprotein platform targeting the Kv1.3 ion channel is progressing toward clinical development, and AI-assisted design has materially accelerated preclinical timelines. The involvement of Austrian partner AOP Health provides commercial and scientific validation, but manufacturing, quality control and toxicology work must still be completed before regulators will consider first-in-human trials. Parallel programs spun out from VRG include a switchable gene-therapy approach (CREATe Therapeutics) and a migraine-prevention combination (Novamigra VRG-145).
